Home > Healthcare & Medical Devices > Hemoglobin Testing Market
Hemoglobin Market size is expected to register significant growth from 2022 to 2028, owing to the increasing awareness regarding testing and diagnosis of blood disorders. Hemoglobin tests are used to measure the amount of hemoglobin present in the blood. Hemoglobin refers to a protein in the red blood cells, which carry oxygen to the organs and tissues and transport CO2 back to the lungs. Hemoglobin testing is done for various purposes, including to diagnose and monitor medical conditions as well as to keep a check on overall health.
The growing burden of chronic ailments like diabetes is a key factor propelling hemoglobin testing market growth over 2022-2028. According to International Diabetes Federation estimates, almost 537 million adults suffer from diabetes in 2021, with the number expected to rise to 643 million by 2030. Since patients diagnosed with diabetes need to keep regular track of their HbA1c and blood glucose levels, this rising prevalence of diabetes will create a surge in demand for hemoglobin testing solutions, particularly hemoglobin A1c (HbA1c) tests. In June 2021, Trivitron Healthcare introduced two novel HbA1c and Hb variant detection tests, including high-performance liquid chromatography (HPLC) analyzers NANO H110 and NANO H5, for detection of HbA1c in under three minutes. These HPLC-based HbA1c analyzers are designed to monitor conditions like thalassemia, diabetes, and hemoglobin variants.
Based on product, the hemoglobin testing market from the point-of-care segment is poised to gain major traction by 2028. This is driven mainly by the growing use of advanced digital technologies in combination with various techniques. In anemia management, the use of AI (artificial intelligence) has triggered significant evolution, particularly in point-of-care setups. For instance, in January 2021, Bosch introduced a new portable HMS (Hemoglobin Monitor Solution), designed to be used in regions where medical access is limited, by providing rapid screening for anemia using a non-invasive, safe approach. Developed as a pain-free point-of-care solution, the device uses machine learning algorithms to detect hemoglobin levels, through multi-wave spectrophotometry-led finger scanning.
Regionally, the Asia Pacific hemoglobin testing market is projected to depict a strong growth rate through 2028, owing to the increasing prevalence of diabetes in the region. Based on estimates from IDF, in 2021, over 90 million adults are living with diabetes in the SEA (South-East Asia) region, a figure that is likely to rise to 113 million by 2030. Given this rise in the diabetic patient population, the need for efficient blood glucose and hemoglobin monitoring will become crucial, thereby boosting hemoglobin testing industry penetration in the region.
Key players operating in the hemoglobin testing market include EKF Diagnostics Holdings (IBL plc), Abbott Laboratories, F. Hoffmann-La Roche, ACON Laboratories, Sysmex Corporation, Bio-Rad Laboratories, Wrig Nanosystems Pvt. Ltd, Danaher, Quest Diagnostics, and Nova Biomedical. Strategic initiatives implemented by these entities range from mergers and acquisitions to new product launches, among others.
In November 2020, Bio-Rad Laboratories, Inc. introduced novel features to its D-10 Hemoglobin Testing System, which delivers fully automated testing for beta-thalassemia and diabetes on a single platform, for diabetes clinics and clinical labs with low to medium volume. These improvements were made for better management of patient results, quality control optimization, and compliance with customer requirements and workflows. In March 2021, Sysmex Corporation introduced new products to its hematology product portfolio, including the XR-Series Automated Hematology Analyzer, its next-gen flagship model, the XQ-Series Automated Hematology Analyzer, a compact 3-part WBC differential model, with an aim to optimize operations at testing labs for compliance with regional facility needs and characteristics.
Prior to the novel coronavirus outbreak, point-of-care HbA1c testing was conducted predominantly at physical facilities for diabetic patients. Following the outbreak, however, many patients were forced to move their routine care from in-person visits to online or telehealth consultation. Consequently, HbA1c testing witnessed a drastic impact, with point-of-care testing volumes declining by nearly 80% at the peak of the pandemic’s first wave. Given this significant decline in HbA1c testing volume, the hemoglobin testing market, in general, may have witnessed certain roadblocks during the initial months of the pandemic. However, since regular testing of HbA1c and blood glucose level is a crucial aspect of care for diabetic patients, efforts are being made to improve hemoglobin testing in recent months. These include the development of remote blood sampling programs, which can enable patients to collect blood samples at home and send them for analysis to laboratories. Implementation of such programs will not only help enhance HbA1c testing but will also address the challenges of hemoglobin testing underutilization over the foreseeable future.
Market, by Product
Market, by Technology
Market, by End-use
The above information is provided for the following regions and countries: